Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.35 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.35 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.35 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.35 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.35 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.35 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.35 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.35 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.35 |
| ▸ | CHRNB4 known ✓ | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 known ✓ | P32297 | 2/20 | 0.33 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL938287 | 1.00 | TSHR (0.38) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL12908892 | 0.98 | TSHR (0.39) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL13372683 | 0.98 | TSHR (0.39) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL18904850 | 0.81 | CHRNB2 (0.34) | ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19547934 | 0.79 | ALDH1A1 (0.35) | TDP1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL28997967 | 0.79 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20711835 | 0.79 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL31064094 | 0.79 | ALDH1A1 (0.35) | TDP1ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL665365 | 0.78 | TSHR (0.44) | TSHRGABRR1GABRR2BLMGABRR3 | |
| Hydrochloric Acid SCHEMBL665366 | 0.78 | TSHR (0.44) | TSHRGABRR1GABRR2BLMGABRR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113768935-A | Prophylactic and/or therapeutic agent for immune diseases | 大鹏药品工业株式会社 | 2021-12-10 | — | — | CN | disclosed |
| CN-107206001-B | Prophylactic and/or therapeutic agent for immune diseases | 大鹏药品工业株式会社 | 2021-09-28 | — | — | CN | disclosed |
| EP-3486244-A1 | NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-05-22 | — | — | EP | disclosed |
| EP-3120852-B1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR IMMUNE DISEASES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2019-05-01 | — | — | EP | disclosed |
| EP-2947086-B1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2018-01-03 | — | — | EP | disclosed |
| EP-3037424-B1 | NOVEL QUINOLINE-SUBSTITUTED COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-9782412-B2 | Preventive and/or therapeutic agent of immune disease | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9758526-B2 | Quinoline-substituted compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9650386-B2 | Quinoline-substituted compound | Taiho Pharmaceutical Co., Inc. (JP) | 2017-05-16 | — | — | US | disclosed |
| US-20170101414-A1 | NOVEL QUINOLINE-SUBSTITUTED COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-04-13 | — | — | US | disclosed |
| US-9580432-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20170042900-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT OF IMMUNE DISEASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| EP-3120852-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR IMMUNE DISEASES | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-20160194332-A1 | NOVEL QUINOLINE -SUBSTITUTED COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| EP-3037424-A1 | NOVEL QUINOLINE-SUBSTITUTED COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-06-29 | — | — | EP | disclosed |
| US-20160115168-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-04-28 | — | — | US | disclosed |
| EP-2947086-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2212332-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101414-A1 | NOVEL QUINOLINE-SUBSTITUTED COMPOUND | EGFR, ERBB2, ERBB4 | GABRP 3322/4885GABRD 4162/4885GABRA1 2614/4885 |
| US-20160194332-A1 | NOVEL QUINOLINE -SUBSTITUTED COMPOUND | EGFR, ERBB2, ERBB4 | GABRP 3322/4885GABRD 4162/4885GABRA1 2614/4885 |
| US-20170042900-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT OF IMMUNE DISEASE | BTK, SYK, MYD88 | GABRP 3631/4885GABRD 4019/4885GABRA1 2342/4885 |
| US-20160115168-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | BTK, JAK2, SYK | GABRP 3415/4885GABRD 3913/4885GABRA1 3330/4885 |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, CYP11B1, CYP11A1 | GABRP 4170/4885GABRD 3459/4885GABRA1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.